Search
Brexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalAs of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically … for the treatment of postpartum depression (PPD) in adult females [F4066].
Ursodeoxycholic acid
go.drugbank.com/drugs/DB01586ApprovedInvestigational[A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996. … [A256272,A256277] UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years.
Mixtures: BAMBOO SALT Eunganggo Jook Yeom, BAMBOO SALT Eunganggo Jook Yeom ToothpasteClobetasone
go.drugbank.com/drugs/DB13158ApprovedClobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions
Products: U-CLOSONE CREAM, U-CLOSONE OINTMENTNogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigational[L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … [L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin (
Ibrexafungerp
go.drugbank.com/drugs/DB12471ApprovedIbrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast … [A235384,L34349] It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals.
Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseNatural Killer Cell
go.drugbank.com/drugs/DB15721InvestigationalGenerally, the number of NK cells collected in the peripheral blood mononuclear cell (PBMC) is too low for sufficient potency, and ex vivo expansion is performed. … Other techniques involve using umbilical cord blood (UCB) directly; these NK cells have heterogeneous CD56 expression but are considered suitable for immunotherapy.
Synonyms: NK CellsPentazocine
go.drugbank.com/drugs/DB00652ApprovedVet approvedThe first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Icatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigational[A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … results obtained from 3 double-blind, randomized, controlled clinical trials known as FAST 1, 2, and 3, where a median time to almost complete symptom relief was observed to be 8 hours compared to 36 hours for
Medrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnIt was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.
Vamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain